• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

    10/26/22 10:07:48 AM ET
    $ABT
    $AGYS
    $ALLY
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $ABT alert in real time by email

    Upgrades

    For Enterprise Financial Services Corp (NASDAQ:EFSC), DA Davidson upgraded the previous rating of Neutral to Buy. For the third quarter, Enterprise Finl Servs had an EPS of $1.32, compared to year-ago quarter EPS of $1.27. The stock has a 52-week-high of $51.50 and a 52-week-low of $39.63. At the end of the last trading period, Enterprise Finl Servs closed at $50.84.

    Goldman Sachs upgraded the previous rating for Biogen Inc (NASDAQ:BIIB) from Neutral to Buy. For the third quarter, Biogen had an EPS of $4.77, compared to year-ago quarter EPS of $4.77. At the moment, the stock has a 52-week-high of $283.44 and a 52-week-low of $187.16. Biogen closed at $273.56 at the end of the last trading period.

    According to CJS Securities, the prior rating for Vicor Corp (NASDAQ:VICR) was changed from Market Perform to Market Outperform. Vicor earned $0.18 in the third quarter, compared to $0.29 in the year-ago quarter. At the moment, the stock has a 52-week-high of $128.96 and a 52-week-low of $42.90. Vicor closed at $48.62 at the end of the last trading period.

    For Agilysys Inc (NASDAQ:AGYS), Craig-Hallum upgraded the previous rating of Hold to Buy. For the second quarter, Agilysys had an EPS of $0.24, compared to year-ago quarter EPS of $0.18. The current stock performance of Agilysys shows a 52-week-high of $57.45 and a 52-week-low of $31.49. Moreover, at the end of the last trading period, the closing price was at $54.86.

    For Range Resources Corp (NYSE:RRC), Susquehanna upgraded the previous rating of Neutral to Positive. Range Resources earned $1.37 in the third quarter, compared to $0.52 in the year-ago quarter. The stock has a 52-week-high of $37.44 and a 52-week-low of $16.71. At the end of the last trading period, Range Resources closed at $28.60.

    For Liberty Energy Inc (NYSE:LBRT), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Liberty Energy showed an EPS of $0.78, compared to $0.22 from the year-ago quarter. The stock has a 52-week-high of $20.05 and a 52-week-low of $9.74. At the end of the last trading period, Liberty Energy closed at $15.85.

    For Humana Inc (NYSE:HUM), Deutsche Bank upgraded the previous rating of Hold to Buy. Humana earned $8.67 in the second quarter, compared to $6.89 in the year-ago quarter. The stock has a 52-week-high of $540.20 and a 52-week-low of $351.20. At the end of the last trading period, Humana closed at $529.46.

    BTIG upgraded the previous rating for Helix Energy Solutions Group Inc (NYSE:HLX) from Neutral to Buy. In the third quarter, Helix Energy Solutions Gr showed an EPS of $0.12, compared to $0.13 from the year-ago quarter. The current stock performance of Helix Energy Solutions Gr shows a 52-week-high of $5.78 and a 52-week-low of $2.47. Moreover, at the end of the last trading period, the closing price was at $5.18.

    According to Morgan Stanley, the prior rating for Discover Financial Services (NYSE:DFS) was changed from Equal-Weight to Overweight. Discover Financial earned $3.54 in the third quarter, compared to $3.54 in the year-ago quarter. The current stock performance of Discover Financial shows a 52-week-high of $130.81 and a 52-week-low of $87.64. Moreover, at the end of the last trading period, the closing price was at $99.97.

    According to Wells Fargo, the prior rating for Halliburton Co (NYSE:HAL) was changed from Equal-Weight to Overweight. In the third quarter, Halliburton showed an EPS of $0.60, compared to $0.28 from the year-ago quarter. At the moment, the stock has a 52-week-high of $43.99 and a 52-week-low of $23.01. Halliburton closed at $34.98 at the end of the last trading period.

    See all analyst ratings upgrades.

    Downgrades

    According to Fox Advisors, the prior rating for Corning Inc (NYSE:GLW) was changed from Overweight to Equal-Weight. For the third quarter, Corning had an EPS of $0.51, compared to year-ago quarter EPS of $0.56. The stock has a 52-week-high of $43.47 and a 52-week-low of $28.98. At the end of the last trading period, Corning closed at $31.73.

    For Independent Bank Group Inc (NASDAQ:IBTX), Hovde Group downgraded the previous rating of Outperform to Market Perform. In the third quarter, Independent Bank Gr showed an EPS of $1.33, compared to $1.22 from the year-ago quarter. The stock has a 52-week-high of $79.66 and a 52-week-low of $61.16. At the end of the last trading period, Independent Bank Gr closed at $63.22.

    According to Hovde Group, the prior rating for Peoples Bancorp Inc (Marietta OH) (NASDAQ:PEBO) was changed from Outperform to Market Perform. For the third quarter, Peoples Bancorp had an EPS of $0.92, compared to year-ago quarter EPS of $0.28. The current stock performance of Peoples Bancorp shows a 52-week-high of $34.63 and a 52-week-low of $25.63. Moreover, at the end of the last trading period, the closing price was at $28.55.

    For First Foundation Inc (NASDAQ:FFWM), DA Davidson downgraded the previous rating of Buy to Neutral. First Foundation earned $0.51 in the third quarter, compared to $0.83 in the year-ago quarter. The current stock performance of First Foundation shows a 52-week-high of $28.01 and a 52-week-low of $16.23. Moreover, at the end of the last trading period, the closing price was at $16.45.

    For Myovant Sciences Ltd (NYSE:MYOV), Evercore ISI Group downgraded the previous rating of Outperform to In-Line. In the second quarter, Myovant Sciences showed an EPS of $0.47, compared to $0.75 from the year-ago quarter.

    According to Goldman Sachs, the prior rating for Edgewell Personal Care Co (NYSE:EPC) was changed from Buy to Neutral. Edgewell Personal Care earned $0.86 in the third quarter, compared to $0.89 in the year-ago quarter. The current stock performance of Edgewell Personal Care shows a 52-week-high of $51.86 and a 52-week-low of $32.00. Moreover, at the end of the last trading period, the closing price was at $40.20.

    According to Compass Point, the prior rating for Ally Financial Inc (NYSE:ALLY) was changed from Buy to Neutral. For the third quarter, Ally Financial had an EPS of $1.12, compared to year-ago quarter EPS of $2.16. At the moment, the stock has a 52-week-high of $53.83 and a 52-week-low of $25.33. Ally Financial closed at $27.12 at the end of the last trading period.

    For Whirlpool Corp (NYSE:WHR), B of A Securities downgraded the previous rating of Neutral to Underperform. For the third quarter, Whirlpool had an EPS of $4.49, compared to year-ago quarter EPS of $6.68. The stock has a 52-week-high of $245.44 and a 52-week-low of $124.43. At the end of the last trading period, Whirlpool closed at $137.00.

    Credit Suisse downgraded the previous rating for Invesco Ltd (NYSE:IVZ) from Neutral to Underperform. For the third quarter, Invesco had an EPS of $0.34, compared to year-ago quarter EPS of $0.77. The stock has a 52-week-high of $25.33 and a 52-week-low of $13.20. At the end of the last trading period, Invesco closed at $15.05.

    According to Raymond James, the prior rating for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was changed from Market Perform to Underperform. In the second quarter, Regeneron Pharmaceuticals showed an EPS of $9.77, compared to $25.80 from the year-ago quarter. At the moment, the stock has a 52-week-high of $761.04 and a 52-week-low of $538.01. Regeneron Pharmaceuticals closed at $747.33 at the end of the last trading period.

    According to Wells Fargo, the prior rating for Baker Hughes Co (NASDAQ:BKR) was changed from Overweight to Equal-Weight. In the third quarter, Baker Hughes showed an EPS of $0.26, compared to $0.16 from the year-ago quarter. At the moment, the stock has a 52-week-high of $39.78 and a 52-week-low of $20.41. Baker Hughes closed at $26.10 at the end of the last trading period.

    According to Compass Point, the prior rating for Washington Trust Bancorp Inc (NASDAQ:WASH) was changed from Buy to Neutral. For the third quarter, Washington Trust Bancorp had an EPS of $1.08, compared to year-ago quarter EPS of $1.07. The current stock performance of Washington Trust Bancorp shows a 52-week-high of $60.96 and a 52-week-low of $45.60. Moreover, at the end of the last trading period, the closing price was at $48.76.

    According to Goldman Sachs, the prior rating for Silvergate Capital Corp (NYSE:SI) was changed from Buy to Neutral. Silvergate Capital earned $1.28 in the third quarter, compared to $0.88 in the year-ago quarter. The current stock performance of Silvergate Capital shows a 52-week-high of $162.65 and a 52-week-low of $50.65. Moreover, at the end of the last trading period, the closing price was at $60.67.

    JP Morgan downgraded the previous rating for Crown Holdings Inc (NYSE:CCK) from Overweight to Neutral. Crown Holdings earned $1.46 in the third quarter, compared to $2.03 in the year-ago quarter. The current stock performance of Crown Holdings shows a 52-week-high of $130.42 and a 52-week-low of $66.00. Moreover, at the end of the last trading period, the closing price was at $70.69.

    See all analyst ratings downgrades.

    Initiations

    With a Buy rating, Ladenburg Thalmann initiated coverage on Capricor Therapeutics Inc (NASDAQ:CAPR). The price target seems to have been set at $15.00 for Capricor Therapeutics. Capricor Therapeutics earned $0.29 in the second quarter, compared to $0.22 in the year-ago quarter. The current stock performance of Capricor Therapeutics shows a 52-week-high of $6.58 and a 52-week-low of $2.56. Moreover, at the end of the last trading period, the closing price was at $5.73.

    EF Hutton initiated coverage on SHF Holdings Inc (NASDAQ:SHFS) with a Buy rating. The price target for SHF Hldgs is set to $10.50. At the moment, the stock has a 52-week-high of $13.60 and a 52-week-low of $2.30. SHF Hldgs closed at $2.92 at the end of the last trading period.

    With a Neutral rating, Mizuho initiated coverage on Abbott Laboratories (NYSE:ABT). The price target seems to have been set at $105.00 for Abbott Laboratories. For the third quarter, Abbott Laboratories had an EPS of $1.15, compared to year-ago quarter EPS of $1.40. The current stock performance of Abbott Laboratories shows a 52-week-high of $139.83 and a 52-week-low of $93.25. Moreover, at the end of the last trading period, the closing price was at $97.95.

    With a Buy rating, HC Wainwright & Co. initiated coverage on Geovax Labs Inc (NASDAQ:GOVX). The price target seems to have been set at $8.00 for Geovax Labs. In the second quarter, Geovax Labs showed an EPS of $0.18, compared to $0.21 from the year-ago quarter. The current stock performance of Geovax Labs shows a 52-week-high of $4.30 and a 52-week-low of $0.55. Moreover, at the end of the last trading period, the closing price was at $0.87.

    Piper Sandler initiated coverage on Roblox Corp (NYSE:RBLX) with an Overweight rating. The price target for Roblox is set to $54.00. For the second quarter, Roblox had an EPS of $0.30, compared to year-ago quarter EPS of $0.25. The current stock performance of Roblox shows a 52-week-high of $103.79 and a 52-week-low of $21.65. Moreover, at the end of the last trading period, the closing price was at $45.71.

    With a Neutral rating, Mizuho initiated coverage on Teleflex Inc (NYSE:TFX). The price target seems to have been set at $220.00 for Teleflex. Teleflex earned $3.39 in the second quarter, compared to $3.35 in the year-ago quarter. At the moment, the stock has a 52-week-high of $356.72 and a 52-week-low of $182.65. Teleflex closed at $204.39 at the end of the last trading period.

    With a Buy rating, Mizuho initiated coverage on Edwards Lifesciences Corp (NYSE:EW). The price target seems to have been set at $100.00 for Edwards Lifesciences. In the second quarter, Edwards Lifesciences showed an EPS of $0.63, compared to $0.64 from the year-ago quarter. The stock has a 52-week-high of $131.10 and a 52-week-low of $80.69. At the end of the last trading period, Edwards Lifesciences closed at $85.70.

    With a Buy rating, DA Davidson initiated coverage on Roblox Corp (NYSE:RBLX). The price target seems to have been set at $55.00 for Roblox. Roblox earned $0.30 in the second quarter, compared to $0.25 in the year-ago quarter. The stock has a 52-week-high of $103.79 and a 52-week-low of $21.65. At the end of the last trading period, Roblox closed at $45.71.

    See all analyst ratings initiations.

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $AGYS
    $ALLY
    $BIIB

    CompanyDatePrice TargetRatingAnalyst
    Crown Holdings Inc.
    $CCK
    2/9/2026$126.00Buy → Neutral
    UBS
    Roblox Corporation
    $RBLX
    2/9/2026$84.00Neutral → Buy
    Roth Capital
    Biogen Inc.
    $BIIB
    2/9/2026$194.00 → $228.00Buy
    H.C. Wainwright
    Roblox Corporation
    $RBLX
    2/6/2026$159.00 → $105.00Buy
    Needham
    Crown Holdings Inc.
    $CCK
    2/6/2026Outperform → Peer Perform
    Wolfe Research
    Crown Holdings Inc.
    $CCK
    2/6/2026$155.00Overweight → Neutral
    Analyst
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Liberty Energy Inc.
    $LBRT
    2/2/2026$32.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $ABT
    $AGYS
    $ALLY
    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Keating Melvin L bought $50,379 worth of shares (600 units at $83.96), increasing direct ownership by 2% to 35,007 units (SEC Form 4)

    4 - AGILYSYS INC (0000078749) (Issuer)

    2/3/26 3:02:52 PM ET
    $AGYS
    EDP Services
    Technology

    Chief Financial Officer Hutchinson Russell E. bought $499,307 worth of shares (11,566 units at $43.17), increasing direct ownership by 5% to 225,336 units (SEC Form 4)

    4 - Ally Financial Inc. (0000040729) (Issuer)

    1/28/26 4:48:14 PM ET
    $ALLY
    Major Banks
    Finance

    $ABT
    $AGYS
    $ALLY
    $BIIB
    SEC Filings

    View All

    SEC Form 8-K filed by Biogen Inc.

    8-K - BIOGEN INC. (0000875045) (Filer)

    2/11/26 5:07:38 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Roblox Corporation

    S-8 - Roblox Corp (0001315098) (Filer)

    2/11/26 4:24:07 PM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-K filed by Whirlpool Corporation

    10-K - WHIRLPOOL CORP /DE/ (0000106640) (Filer)

    2/11/26 4:23:28 PM ET
    $WHR
    Consumer Electronics/Appliances
    Consumer Discretionary

    $ABT
    $AGYS
    $ALLY
    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biogen Announces Board Chair Transition

    CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that the Board of Directors has elected Dr. Maria C. Freire as Chair of the Board of Directors, effective immediately following the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting"), scheduled to take place on June 9, 2026. Dr. Freire will succeed Caroline Dorsa who has decided to retire from the Biogen Board of Directors and not to stand for reelection at the Annual Meeting. Dr. Freire joined the Biogen Board in 2021 and serves on the Corporate Governance Committee and on the Compensation and Management Development Committee. Ms. Dorsa said: "It has been an honor to serve on t

    2/11/26 5:00:00 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Regeneron Announces Investor Conference Presentations

    TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday, March 4, 2026Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday, March 11, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops and commerciali

    2/11/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corning Announces Quarterly Dividend

    Corning Incorporated's (NYSE:GLW) Board of Directors today declared a quarterly dividend of $0.28 per share. The dividend will be payable on March 30, 2026, to shareholders of record on February 27, 2026. Caution Concerning Forward-Looking Statements The statements contained in this release and related comments by management that are not historical facts or information and contain words such as "will," "believe," "anticipate," "expect," "intend," "plan," "seek," "see," "would," "target," "estimate," "forecast" or similar expressions are forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform

    2/11/26 2:49:00 PM ET
    $GLW
    Telecommunications Equipment
    Industrials

    $ABT
    $AGYS
    $ALLY
    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Infra & Performance Ofcr Apostolides James E sold $1,542,726 worth of shares (25,824 units at $59.74) and exercised 10,989 shares at a strike of $22.98, decreasing direct ownership by 49% to 15,449 units (SEC Form 4)

    4 - Baker Hughes Co (0001701605) (Issuer)

    2/11/26 8:00:16 PM ET
    $BKR
    Oil and Gas Field Machinery
    Consumer Discretionary

    Chief Legal Officer Magno Maria Georgia sold $1,131,956 worth of shares (19,150 units at $59.11), decreasing direct ownership by 57% to 14,588 units (SEC Form 4)

    4 - Baker Hughes Co (0001701605) (Issuer)

    2/11/26 7:56:32 PM ET
    $BKR
    Oil and Gas Field Machinery
    Consumer Discretionary

    Chief Growth & Experience Ofcr Borras Maria C sold $3,217,594 worth of shares (54,434 units at $59.11), decreasing direct ownership by 37% to 92,035 units (SEC Form 4)

    4 - Baker Hughes Co (0001701605) (Issuer)

    2/11/26 7:54:45 PM ET
    $BKR
    Oil and Gas Field Machinery
    Consumer Discretionary

    $ABT
    $AGYS
    $ALLY
    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

    3/25/24 4:41:37 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABT
    $AGYS
    $ALLY
    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Crown downgraded by UBS with a new price target

    UBS downgraded Crown from Buy to Neutral and set a new price target of $126.00

    2/9/26 6:59:50 AM ET
    $CCK
    Containers/Packaging
    Industrials

    Roblox upgraded by Roth Capital with a new price target

    Roth Capital upgraded Roblox from Neutral to Buy and set a new price target of $84.00

    2/9/26 6:58:32 AM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology

    H.C. Wainwright reiterated coverage on Biogen with a new price target

    H.C. Wainwright reiterated coverage of Biogen with a rating of Buy and set a new price target of $228.00 from $194.00 previously

    2/9/26 6:43:59 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABT
    $AGYS
    $ALLY
    $BIIB
    Leadership Updates

    Live Leadership Updates

    View All

    Ally Appoints Distinguished Financial Services Executive and Former Regulator Rodney Hood as Senior Policy Advisor to the CEO

    CHARLOTTE, N.C., Jan. 27, 2026 /PRNewswire/ -- Ally Financial Inc. (NYSE:ALLY) today announced the appointment of Rodney Hood as a senior policy advisor to the CEO. In this role, Hood will leverage his nearly three decades of leadership in banking, regulation, risk management and financial inclusion to provide invaluable counsel on political affairs and D.C. engagement, further strengthening Ally's voice in critical policy discussions.  Hood brings an unparalleled depth of experience to Ally, having held multiple presidential appointments across two administrations. He notably

    1/27/26 10:00:00 AM ET
    $ALLY
    Major Banks
    Finance

    Washington Trust expands commercial banking with new institutional banking team

    Builds on strategic leadership hire and positions company for growth WESTERLY, R.I. , Jan. 21, 2026 /PRNewswire/ -- Washington Trust is expanding and enhancing its focus on commercial banking with the addition of a dedicated institutional banking team to serve the unique needs of independent schools, private colleges and universities, healthcare and human service providers, and cultural institutions throughout the Northeast region.  The team is led by Gerald S. "Jerry" Algere, senior vice president and managing director, institutional banking, who has 35 years of experience bu

    1/21/26 12:30:00 PM ET
    $WASH
    Major Banks
    Finance

    PEOPLES BANCORP INC. ANNOUNCES RETIREMENT OF DOUGLAS V. WYATT; RON J. MAJKA APPOINTED CHIEF COMMERCIAL BANKING OFFICER

    MARIETTA, Ohio, Jan. 16, 2026 /PRNewswire/ -- Peoples Bancorp Inc. ("Peoples") (NASDAQ:PEBO) today announced that Douglas V. Wyatt will retire from his positions with Peoples and its banking subsidiary, Peoples Bank, effective April 3, 2026. Mr. Wyatt has served as Executive Vice President, Chief Commercial Banking Officer, of Peoples and Peoples Bank since 2017. With the notification of Mr. Wyatt's retirement, each of the Peoples Board of Directors and the Peoples Bank Board of Directors has appointed Ron J. Majka to serve in the position of Executive Vice President, Chief Commercial Banking Officer, of Peoples and Peoples Bank, respectively, in each case effective April 4, 2026. "On behal

    1/16/26 4:05:00 PM ET
    $PEBO
    Major Banks
    Finance

    $ABT
    $AGYS
    $ALLY
    $BIIB
    Financials

    Live finance-specific insights

    View All

    Corning Announces Quarterly Dividend

    Corning Incorporated's (NYSE:GLW) Board of Directors today declared a quarterly dividend of $0.28 per share. The dividend will be payable on March 30, 2026, to shareholders of record on February 27, 2026. Caution Concerning Forward-Looking Statements The statements contained in this release and related comments by management that are not historical facts or information and contain words such as "will," "believe," "anticipate," "expect," "intend," "plan," "seek," "see," "would," "target," "estimate," "forecast" or similar expressions are forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform

    2/11/26 2:49:00 PM ET
    $GLW
    Telecommunications Equipment
    Industrials

    Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance

    Reports 4Q25 net loss per share of $6.61 on a GAAP basis, Adjusted net loss per share of $3.96; reports full year (FY) 2025 earnings per share (EPS) of $9.84 on a GAAP basis, $17.14 on an Adjusted basis; quarterly and FY Adjusted results in line with management's expectations 4Q25 Insurance segment GAAP benefit ratio of 93.1 percent; FY 2025 Insurance segment GAAP benefit ratio of 90.4 percent, slightly better than guidance of 'the top end of the range of 90.1 percent to 90.5 percent' Introduces FY 2026 GAAP EPS guidance of 'at least $8.89'; 'at least $9.00' on an Adjusted basis; the anticipated year-over-year decline results from the Star Ratings headwind for Bonus Year 2026, net of

    2/11/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Edwards Lifesciences Reports Fourth Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $

    2/10/26 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    $ABT
    $AGYS
    $ALLY
    $BIIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vicor Corporation

    SC 13G/A - VICOR CORP (0000751978) (Subject)

    12/4/24 2:38:58 PM ET
    $VICR
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13G/A filed by Corning Incorporated

    SC 13G/A - CORNING INC /NY (0000024741) (Subject)

    11/22/24 6:06:27 AM ET
    $GLW
    Telecommunications Equipment
    Industrials

    Amendment: SEC Form SC 13G/A filed by Roblox Corporation

    SC 13G/A - Roblox Corp (0001315098) (Subject)

    11/14/24 5:47:35 PM ET
    $RBLX
    Computer Software: Prepackaged Software
    Technology